Alto Neuroscience, Inc. (NYSE:ANRO) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) have been assigned an average rating of “Moderate Buy” from the six brokerages that are covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $16.75.

Separately, William Blair restated an “outperform” rating on shares of Alto Neuroscience in a research report on Friday, March 21st.

Institutional Investors Weigh In On Alto Neuroscience

A number of institutional investors have recently made changes to their positions in the stock. Wells Fargo & Company MN grew its holdings in Alto Neuroscience by 40.0% during the fourth quarter. Wells Fargo & Company MN now owns 10,989 shares of the company’s stock valued at $46,000 after purchasing an additional 3,139 shares during the period. Deutsche Bank AG lifted its holdings in shares of Alto Neuroscience by 31.3% during the 4th quarter. Deutsche Bank AG now owns 15,210 shares of the company’s stock valued at $64,000 after purchasing an additional 3,629 shares in the last quarter. BNP Paribas Financial Markets increased its stake in Alto Neuroscience by 619.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock worth $49,000 after purchasing an additional 3,715 shares in the last quarter. Rhumbline Advisers lifted its stake in Alto Neuroscience by 24.4% in the fourth quarter. Rhumbline Advisers now owns 25,556 shares of the company’s stock valued at $108,000 after buying an additional 5,008 shares in the last quarter. Finally, Philadelphia Financial Management of San Francisco LLC boosted its holdings in shares of Alto Neuroscience by 1.5% in the third quarter. Philadelphia Financial Management of San Francisco LLC now owns 449,952 shares of the company’s stock valued at $5,147,000 after buying an additional 6,663 shares during the period.

Alto Neuroscience Trading Down 3.4 %

Shares of Alto Neuroscience stock opened at $2.56 on Friday. The firm has a market capitalization of $69.04 million and a PE ratio of -1.01. The company’s fifty day moving average price is $3.56 and its two-hundred day moving average price is $5.90. Alto Neuroscience has a 52-week low of $2.53 and a 52-week high of $18.35. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.10 and a quick ratio of 13.09.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.09. On average, analysts expect that Alto Neuroscience will post -2.54 EPS for the current year.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.